Navigation Links
Paragon Bioservices Appoints Dr. Vadim Klyushnichenko as Vice President of Preclinical Services and Process Development
Date:7/20/2011

BALTIMORE, July 20, 2011 /PRNewswire/ -- Paragon Bioservices, Inc., a Baltimore-based contract research and GMP manufacturing organization, announced today the appointment of Vadim Klyushnichenko, Ph.D. as Vice President, Preclinical Services and Process Development.  He will report to Paragon's President and CEO Marco Chacon, Ph.D.

Dr. Klyushnichenko has more than 15 years experience in biopharmaceutical project management, analytical development and formulation, process development, engineering and scale-up from pilot to GMP manufacturing, technology transfer and regulatory filing.

He developed his managerial and scientific background working as Vice President of Drug Development at both Terapio (Austin, TX) and Coldstream Laboratories, Lab Head at Wyeth BioPharma, and Senior Scientist positions at Epic Therapeutics (Baxter), Altus Biologics in Boston and Aventis/Sanofi Pasteur.

Dr. Klyushnichenko received his M.S., Engineering from Moscow Institute of Physics and Technology, and a  Ph.D. in Chemistry from the Shemyakin Institute of Bioorganic Chemistry in Moscow. His additional research in Analytical Biochemistry and Process Development includes the Humboldt University in Berlin, Dusseldorf University, and the Biotechnology Research Institute in Montreal.  He is also a Certified Professional Project Manager (PMP/PMI) and holds a Certificate of Special Studies (CSS) in Administration and Management from Harvard University.

Dr. Chacon stated, "We feel that Vadim will be a great addition to Paragon's team as we continue to add personnel, double our process development and GMP manufacturing and add fill-and-finish capabilities to our facility."

About Paragon Bioservices

Paragon Bioservices is a contract research and manufacturing organization (CMO) that provides a comprehensive portfolio of services—from research services and process development to cGMP manufacturing of monoclonal antibodies, therapeutic proteins, vaccines and VLPs, and stem cells.  The corporate focus is to bridge the translational divide and enable protein and cell-based therapeutics to move into clinical trials.

Media contacts:
Tiberend Strategic Advisors, Inc.
212-827-0020
Tamara Bright: tbright@tiberend.com
or
Claire Sojda: csojda@tiberend.com


'/>"/>
SOURCE Paragon Bioservices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paragon Bioservices to Partner and Exhibit at the 2011 BIO International Convention
2. Paragon Bioservices Launches Second Expansion to Celebrate its 20th Anniversary
3. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
4. HYCOR Appoints Sean-Xavier Neath as Chief Medical Officer to Support Expansion of Product Lines and Enhance Customer Support Offerings
5. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
6. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
7. GenturaDx Appoints Senior Vice President of Research & Development
8. H. D. Smith Appoints Mark de Bruin Corporate Vice President Managed Care
9. OncoSec Medical Appoints Engineering Leader
10. Tris Pharma Appoints Vice President of Human Resources
11. Cepheid Appoints Vice President of Infectious Disease Research & Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... According to the ... now claim the lives of 62 Americans each day.(1) Yet since 2011, the ... distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox Center ...
(Date:4/24/2017)... ANGELES, CA (PRWEB) , ... April 24, 2017 , ... ... picture is worth a thousand words. The good news for single women is that ... for Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “Reflections of God’s ... God. “Reflections of God’s Work” is the creation of published author, Jerri Broglin, a ... comfort. , “I believe this a great eye-opener for those searching for answers, ...
(Date:4/24/2017)... WA (PRWEB) , ... April 24, 2017 , ... ... leading lifestyle brands, work wear distributors and International relief organizations across the globe ... The company also offers lifestyle and work wear collections via insectshield.com . ...
(Date:4/22/2017)... , ... April 22, 2017 , ... Ecommerce sales have ... States estimated to be $394.9 billion. The consequences of rapid innovation and growth ... the limits of technology, it is every business and individual’s job to give something ...
Breaking Medicine News(10 mins):